All In Biotech

Drug Trial Radar · NCT06643130

Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia

A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients With Hypertension and Dyslipidemia

Last checked: Nov 19, 2026Latest source record: Sep 9, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 162 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

162

Planned (sponsor's estimate)

Start

Dec 2, 2024

Primary completion

Apr 2026

Study completion Apr 2026

Sponsor

Lead sponsor
JW PharmaceuticalIndustry
Sponsor type
Industry
First posted
Oct 16, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 19 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Multi-center, Randomized, Double-blind, Parallel, Phase Ⅲ Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of JW0104+C2402 in Patients with Hypertension and Dyslipidemia

Conditions

  • Hypertension
  • Dyslipidemia

Interventions

  • JW0104+C2402Drug

    For 8 weeks(PO (Per Oral), QD)

  • JW0104+C2403Drug

    For 8 weeks(PO, QD)

  • C2402Drug

    For 8 weeks(PO, QD)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in msSBP (Systolic Blood Pressure)Time frame: week 8
  2. Percent change from baseline in LDL-C (Low-Density Lipoprotein Cholesterol)Time frame: week 8

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Gangdong Sacred Heart Hospital

    Seoul, South Korea · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.